Pacific Historical Financial Ratios
| PACB Stock | USD 1.45 0.01 0.68% |
Pacific Biosciences is promptly reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Inventory Turnover of 2.22, Payables Turnover of 6.34, Sales General And Administrative To Revenue of 0.88 or Research And Ddevelopement To Revenue of 0.83 will help investors to properly organize and evaluate Pacific Biosciences financial condition quickly.
Pacific |
About Pacific Financial Ratios Analysis
Pacific BiosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Pacific Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Pacific financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Pacific Biosciences history.
Pacific Biosciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Pacific Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pacific Biosciences sales, a figure that is much harder to manipulate than other Pacific Biosciences of multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Earnings Yield
The inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company.Most ratios from Pacific Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Pacific Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. At present, Pacific Biosciences' PTB Ratio is projected to increase slightly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 4.30, whereas Price To Sales Ratio is forecasted to decline to 3.10.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 11.12 | 7.81 | 8.98 | 9.65 | Intangibles To Total Assets | 0.46 | 0.53 | 0.47 | 0.38 |
Pacific Biosciences fundamentals Correlations
Click cells to compare fundamentals
Pacific Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pacific Biosciences fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 56.87 | 31.92 | 14.31 | 12.41 | 3.26 | 3.1 | |
| Ptb Ratio | 13.37 | 5.27 | 3.26 | 3.55 | 3.19 | 4.3 | |
| Capex To Depreciation | 0.29 | 0.11 | 0.51 | 0.98 | 0.33 | 0.36 | |
| Pb Ratio | 13.37 | 5.27 | 3.26 | 3.55 | 3.19 | 4.3 | |
| Roic | (0.62) | (0.33) | (0.0608) | (0.17) | (0.19) | (0.18) | |
| Inventory Turnover | 4.23 | 3.26 | 2.91 | 1.57 | 2.35 | 2.22 | |
| Net Income Per Share | 0.17 | (0.89) | (1.32) | (1.21) | (1.12) | (1.18) | |
| Payables Turnover | 12.94 | 6.51 | 6.59 | 9.81 | 8.83 | 6.34 | |
| Research And Ddevelopement To Revenue | 0.81 | 0.87 | 1.5 | 0.93 | 0.88 | 0.83 | |
| Pocfratio | 230.04 | (37.47) | (6.98) | (9.6) | (8.64) | (8.21) | |
| Interest Coverage | (390.96) | (14.22) | (20.75) | (23.32) | 26.57 | 27.9 | |
| Capex To Operating Cash Flow | 0.0533 | (0.0533) | (0.0643) | (0.0341) | (0.0307) | (0.0322) | |
| Pfcf Ratio | 242.99 | (35.57) | (6.55) | (9.28) | (8.36) | (7.94) | |
| Income Quality | 0.93 | 0.66 | 0.61 | 0.84 | 0.97 | 0.9 | |
| Roe | (1.42) | 0.0876 | (0.23) | (0.53) | (0.44) | (0.5) | |
| Ev To Operating Cash Flow | 215.85 | (41.91) | (9.38) | (12.51) | (11.26) | (10.7) | |
| Pe Ratio | 152.59 | (22.99) | (6.18) | (8.11) | (1.63) | (1.55) | |
| Return On Tangible Assets | 0.071 | (0.15) | (0.31) | (0.37) | (0.33) | (0.35) | |
| Ev To Free Cash Flow | (9.82) | 228.0 | (39.78) | (8.81) | (12.1) | (10.89) | |
| Earnings Yield | (0.0993) | 0.006554 | (0.0435) | (0.16) | (0.61) | (0.65) | |
| Current Ratio | 9.72 | 13.28 | 11.12 | 7.81 | 8.98 | 9.65 | |
| Receivables Turnover | 4.69 | 5.38 | 6.83 | 5.48 | 6.3 | 9.41 | |
| Revenue Per Share | 0.46 | 0.64 | 0.57 | 0.79 | 0.56 | 0.5 | |
| Debt To Assets | 0.42 | 0.1 | 0.48 | 0.54 | 0.53 | 0.51 | |
| Days Sales Outstanding | 77.9 | 67.79 | 53.44 | 66.65 | 59.98 | 40.3 | |
| Book Value Per Share | 1.94 | 3.88 | 2.51 | 2.77 | 2.49 | 2.61 | |
| Free Cash Flow Yield | (0.1) | 0.004115 | (0.0281) | (0.15) | (0.11) | (0.0969) | |
| Operating Cash Flow Per Share | 0.11 | (0.55) | (1.17) | (1.02) | (0.92) | (0.97) | |
| Ev To Sales | 53.36 | 35.7 | 19.24 | 16.17 | 14.55 | 15.28 | |
| Free Cash Flow Per Share | 0.11 | (0.58) | (1.25) | (1.06) | (0.95) | (1.0) | |
| Days Of Inventory On Hand | 112.11 | 125.31 | 231.98 | 140.02 | 161.02 | 158.79 | |
| Capex To Revenue | 0.0132 | 0.0454 | 0.13 | 0.0441 | 0.0507 | 0.0482 | |
| Cash Per Share | 3.21 | 5.13 | 3.44 | 2.49 | 2.86 | 2.72 | |
| Days Payables Outstanding | 28.2 | 56.04 | 55.38 | 37.21 | 42.79 | 55.3 | |
| Net Debt To E B I T D A | (7.1) | (1.97) | (2.24) | (2.72) | (3.13) | (2.97) | |
| Tangible Book Value Per Share | 1.94 | (0.15) | (1.15) | (0.86) | (0.77) | (0.81) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share | Quarterly Revenue Growth (0.33) | Return On Assets | Return On Equity |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.